Business
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
CALGARY, Alberta, March 05, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the &#...
About this update from Xortx Therapeutics, Inc.
[{"type":"text","content":"XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders \nCALGARY, Alberta, March 05, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (\"XORTX\" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that it has filed its notice of meeting, management information circular (the “Circular”) and related documents (collectively, the “Meeting Materials”) with securities regulators in connection with its upcoming Annual and Special Meeting (the “Meeting”) of holders of common shares (“Shareholders”). The Meeting Materials have also been mailed to Shareholders and can be accessed online on XORTX’s website at this link, under the Company’s SEDAR+ profile (www.sedarplus.ca) and the SEC’s website (www.sec.gov). The mailing of the Circular and related Meeting materials occurred on March 2, 2026. Meeting Details The Meeting will be held on March 24, 2026 at 10:00 am (Calgary Time) at the offices of the Company at 3710 – 33rd Street NW, Calgary, Alberta. At the Meeting, Shareholders will be asked to vote on the following resolutions: To fix the number of directors to be elected at the Meeting at five;To elect directors of the CompanyTo appoint the auditor of the Company for the ensuing year and to authorize the directors of the Company to fix the remuneration of the auditor;To confirm and approve the Company’s stock option plan;To consider and vote on an ordinary resolution to amend the articles of the Company to provide for a consolidation of the Company's common shares on the basis of up to five (5) pre-consolidation common shares for every one (1) post-consolidation common shares as more particularly described in the Management Information Circular of the Company dated February 25, 2026; Shareholders are encouraged to read the Circular for full details on the matters to be considered at the Meeting. Your vote is important no matter how many shares you hold. Vote today. The Board of Directors of XORTX unanimously recommends that Shareholdersvote FOR ALL proposed items Shareholders who have questions or n...